Journal
INTERNATIONAL JOURNAL OF PHARMACEUTICS
Volume 473, Issue 1-2, Pages 599-606Publisher
ELSEVIER
DOI: 10.1016/j.ijpharm.2014.07.054
Keywords
Nanoparticle; Dendrimer; Clinical chemistry test; Enzyme; Protein
Categories
Funding
- Belarusian Republican Foundation for Fundamental Research [B13MS-004]
- National Science Centre of Poland [DEC-2012/04/M/NZ1/00059]
- Marie Curie International Research Staff Exchange Scheme Fellowship within the 7th European Community Framework Programme [PIRSES-GA-2012-316730]
- MINECO [CTQ2011-23245]
- NANODENDMED [S2011/BMD-2351]
- CIBER-BBN - Instituto de Salud Carlos III
Ask authors/readers for more resources
The development of medical nanosystems requires knowledge of their behavior in vivo. Clinical chemistry tests are widely used to estimate the systemic toxicity of nanoparticles. In this paper we have explored the impact of small positively charged nanoparticles-poly(amidoamine), phosphorous and carbosilane dendrimers-on biochemical parameters of standardized serum in vitro. All the dendrimers could shift the main biochemical parameters. Thus, in the case of patients having the normal, but 'boundary', values of biochemical parameters, nanoparticle-induced changes can be wrongly interpreted as evidence of some dysfunctions (hepatic, renal, etc.). Moreover, the effects of nanoparticles of metals, carbon nanotubes, quantum dots, fullerenes, dendrimers having been sized up to 4000 nm and the hundreds of reactive groups, can be significantly higher. Thus, preliminary evaluation of any nanomaterial in vitro is required in clinical chemistry tests before its application in vivo to draw the correct conclusions and benefit animals. (C) 2014 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available